Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia.

Ojamies PN, Kontro M, Edgren H, Ellonen P, Lagström S, Almusa H, Miettinen T, Eldfors S, Tamborero D, Wennerberg K, Heckman C, Porkka K, Wolf M, Kallioniemi O.

Leukemia. 2016 Dec 6. doi: 10.1038/leu.2016.286. [Epub ahead of print]

PMID:
27795554
2.

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia.

Eldfors S, Kuusanmäki H, Kontro M, Majumder MM, Parsons A, Edgren H, Pemovska T, Kallioniemi O, Wennerberg K, Gökbuget N, Burmeister T, Porkka K, Heckman CA.

Leukemia. 2017 Jan;31(1):51-57. doi: 10.1038/leu.2016.202.

3.

Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.

Kangaspeska S, Hultsch S, Jaiswal A, Edgren H, Mpindi JP, Eldfors S, Brück O, Aittokallio T, Kallioniemi O.

BMC Cancer. 2016 Jul 4;16:378. doi: 10.1186/s12885-016-2452-5.

4.

Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers.

Tumiati M, Munne PM, Edgren H, Eldfors S, Hemmes A, Kuznetsov SG.

Oncogene. 2016 Sep 1;35(35):4601-10. doi: 10.1038/onc.2015.528.

PMID:
26820992
5.

Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic Acid-induced 2.

Werner S, Brors B, Eick J, Marques E, Pogenberg V, Parret A, Kemming D, Wood AW, Edgren H, Neubauer H, Streichert T, Riethdorf S, Bedi U, Baccelli I, Jücker M, Eils R, Fehm T, Trumpp A, Johnsen SA, Klefström J, Wilmanns M, Müller V, Pantel K, Wikman H.

Cancer Discov. 2015 May;5(5):506-19. doi: 10.1158/2159-8290.CD-14-1042.

6.

Novel TBL1XR1, EPHA7 and SLFN12 mutations in a Sezary syndrome patient discovered by whole exome sequencing.

Andersson E, Eldfors S, Edgren H, Ellonen P, Väkevä L, Ranki A, Mustjoki S.

Exp Dermatol. 2014 May;23(5):366-8. doi: 10.1111/exd.12405.

PMID:
24689486
7.

Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia.

Kontro M, Kuusanmäki H, Eldfors S, Burmeister T, Andersson EI, Bruserud O, Brümmendorf TH, Edgren H, Gjertsen BT, Itälä-Remes M, Lagström S, Lohi O, Lundán T, Martí JM, Majumder MM, Parsons A, Pemovska T, Rajala H, Vettenranta K, Kallioniemi O, Mustjoki S, Porkka K, Heckman CA.

Leukemia. 2014 Aug;28(8):1738-42. doi: 10.1038/leu.2014.89. No abstract available.

PMID:
24573384
8.

Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.

Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, Almusa H, Bespalov MM, Ellonen P, Elonen E, Gjertsen BT, Karjalainen R, Kulesskiy E, Lagström S, Lehto A, Lepistö M, Lundán T, Majumder MM, Marti JM, Mattila P, Murumägi A, Mustjoki S, Palva A, Parsons A, Pirttinen T, Rämet ME, Suvela M, Turunen L, Västrik I, Wolf M, Knowles J, Aittokallio T, Heckman CA, Porkka K, Kallioniemi O, Wennerberg K.

Cancer Discov. 2013 Dec;3(12):1416-29. doi: 10.1158/2159-8290.CD-13-0350.

9.

Aneuploidy facilitates oncogenic transformation via specific genetic alterations, including Twist2 upregulation.

Högnäs G, Hämälistö S, Rilla K, Laine JO, Vilkki V, Murumägi A, Edgren H, Kallioniemi O, Ivaska J.

Carcinogenesis. 2013 Sep;34(9):2000-9. doi: 10.1093/carcin/bgt171.

PMID:
23689353
10.

The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells.

Sahlberg KK, Hongisto V, Edgren H, Mäkelä R, Hellström K, Due EU, Moen Vollan HK, Sahlberg N, Wolf M, Børresen-Dale AL, Perälä M, Kallioniemi O.

Mol Oncol. 2013 Jun;7(3):392-401. doi: 10.1016/j.molonc.2012.10.012.

11.

A single-nucleotide substitution mutator phenotype revealed by exome sequencing of human colon adenomas.

Nikolaev SI, Sotiriou SK, Pateras IS, Santoni F, Sougioultzis S, Edgren H, Almusa H, Robyr D, Guipponi M, Saarela J, Gorgoulis VG, Antonarakis SE, Halazonetis TD.

Cancer Res. 2012 Dec 1;72(23):6279-89. doi: 10.1158/0008-5472.CAN-12-3869. Erratum in: Cancer Res. 2014 Jan 15;74(2):636.

12.

Reanalysis of RNA-sequencing data reveals several additional fusion genes with multiple isoforms.

Kangaspeska S, Hultsch S, Edgren H, Nicorici D, Murumägi A, Kallioniemi O.

PLoS One. 2012;7(10):e48745. doi: 10.1371/journal.pone.0048745.

13.

Somatic STAT3 mutations in large granular lymphocytic leukemia.

Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, Lagström S, Clemente MJ, Olson T, Jalkanen SE, Majumder MM, Almusa H, Edgren H, Lepistö M, Mattila P, Guinta K, Koistinen P, Kuittinen T, Penttinen K, Parsons A, Knowles J, Saarela J, Wennerberg K, Kallioniemi O, Porkka K, Loughran TP Jr, Heckman CA, Maciejewski JP, Mustjoki S.

N Engl J Med. 2012 May 17;366(20):1905-13. doi: 10.1056/NEJMoa1114885.

14.

KRAS oncogene rearrangements and gene fusions: unexpected rare encounters in late-stage prostate cancers.

Edgren H, Kangaspeska S, Kallioniemi O.

Cancer Discov. 2011 Jun;1(1):12-3. doi: 10.1158/2159-8274.CD-11-0045.

15.

Cytokinesis failure due to derailed integrin traffic induces aneuploidy and oncogenic transformation in vitro and in vivo.

Högnäs G, Tuomi S, Veltel S, Mattila E, Murumägi A, Edgren H, Kallioniemi O, Ivaska J.

Oncogene. 2012 Aug 2;31(31):3597-606. doi: 10.1038/onc.2011.527.

16.

Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer.

Vainio P, Wolf M, Edgren H, He T, Kohonen P, Mpindi JP, Smit F, Verhaegh G, Schalken J, Perälä M, Iljin K, Kallioniemi O.

Prostate. 2012 May 15;72(7):789-802. doi: 10.1002/pros.21487.

PMID:
21919029
17.

An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer.

Mamo A, Cavallone L, Tuzmen S, Chabot C, Ferrario C, Hassan S, Edgren H, Kallioniemi O, Aleynikova O, Przybytkowski E, Malcolm K, Mousses S, Tonin PN, Basik M.

Oncogene. 2012 Apr 19;31(16):2090-100. doi: 10.1038/onc.2011.386.

PMID:
21892209
18.

Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells.

Östling P, Leivonen SK, Aakula A, Kohonen P, Mäkelä R, Hagman Z, Edsjö A, Kangaspeska S, Edgren H, Nicorici D, Bjartell A, Ceder Y, Perälä M, Kallioniemi O.

Cancer Res. 2011 Mar 1;71(5):1956-67. doi: 10.1158/0008-5472.CAN-10-2421.

19.

Identification of fusion genes in breast cancer by paired-end RNA-sequencing.

Edgren H, Murumagi A, Kangaspeska S, Nicorici D, Hongisto V, Kleivi K, Rye IH, Nyberg S, Wolf M, Borresen-Dale AL, Kallioniemi O.

Genome Biol. 2011;12(1):R6. doi: 10.1186/gb-2011-12-1-r6.

20.

Integrative functional genomics analysis of sustained polyploidy phenotypes in breast cancer cells identifies an oncogenic profile for GINS2.

Rantala JK, Edgren H, Lehtinen L, Wolf M, Kleivi K, Vollan HK, Aaltola AR, Laasola P, Kilpinen S, Saviranta P, Iljin K, Kallioniemi O.

Neoplasia. 2010 Nov;12(11):877-88.

Items per page

Supplemental Content

Loading ...
Support Center